Quest Diagnostics Stock (DGX)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Quest Diagnostics is a US laboratory company. It tests blood, urine and tissue samples on behalf of doctors, hospitals, insurers and employers and operates a network of laboratories and collection sites for this purpose. As of Oct 13, 2026

Fact sheet (from the annual report) Medical laboratories · Secaucus, USA

Quest Diagnostics provides insights from laboratory testing that help patients, physicians and organizations make health decisions. The company is divided into the areas Diagnostic Information Services and Diagnostic Solutions. It offers routine tests, specialty tests and advanced clinical tests as well as the examination of tissue samples in pathology. The Diagnostic Solutions area offers risk assessment for life insurers as well as IT for healthcare providers and payers. Its core customers are physicians, hospitals and patients and consumers; other customers include health insurers, employers, government agencies and pharmaceutical companies.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.3%
  • 7 days −0.5%
  • 30 days +8.1%
  • 1 year +37.7%
Day range (last trading day)
−0.3%Price at 13% of the range+1.8%
52-week range
−33.7%Price at 95% of the range+1.9%
Distance from the all-time high
−1.9%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Quest Diagnostics · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 26, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 3.8x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+7.4%
dividend per share, average per year
Coverage by free cash flow
3.8x
covered from 1.0x

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 7
criteria with data met
Revenue per year (5 y)
+3.2%
EPS per year (5 y)
−3.5%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
4 of 8
criteria with data met
Net margin
9.0%
Cash flow ÷ profit
1.80x
backed from 1.0 · 3 years: 1.56x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 4 of 8 met

  • not met: Gross margin above 40% 33.2%
  • not met: Operating margin above 15% 14.1%
  • not met: Net margin above 10% 9.0%
  • not met: Return on equity above 15% 13.8%
  • met: Free cash flow margin above 10% 12.3%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 44.2%
Gross margin

33.2% Fiscal year 2025

Rank 26 of 100: higher than 26% of 370 peers (All). weak.

Rank 15 of 100: higher than 15% of 49 peers (Sector). weak.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

14.1% Fiscal year 2025

Rank 46 of 100: higher than 46% of 470 peers (All). medium.

Rank 45 of 100: higher than 45% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

9.0% Fiscal year 2025

Rank 39 of 100: higher than 39% of 584 peers (All). medium.

Rank 40 of 100: higher than 40% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

13.8% Fiscal year 2025

Rank 52 of 100: higher than 52% of 544 peers (All). medium.

Rank 53 of 100: higher than 53% of 54 peers (Sector). medium.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

6.1% Fiscal year 2025 (total assets at year end)

Rank 57 of 100: higher than 57% of 594 peers (All). medium.

Rank 48 of 100: higher than 48% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

44.2% Fiscal year 2025

Rank 62 of 100: higher than 62% of 595 peers (All). medium.

Rank 50 of 100: higher than 50% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

12.3% Fiscal year 2025

Rank 52 of 100: higher than 52% of 465 peers (All). medium.

Rank 39 of 100: higher than 39% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

1.4B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +3.7%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.2%
  • not met: Over 10 years, revenue grew by more than 5% per year +3.9%
  • not met: Over 3 years, EPS grew by more than 5% per year +3.2%
  • not met: Over 5 years, EPS grew by more than 5% per year −3.5%
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • met: Revenue rose in the last fiscal year +11.8%
Revenue growth 3 years

+3.7% per year

Rank 37 of 100: higher than 37% of 578 peers (All). medium.

Rank 43 of 100: higher than 43% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.2% per year

Rank 17 of 100: higher than 17% of 549 peers (All). weak.

Rank 13 of 100: higher than 13% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+3.9% per year

Rank 29 of 100: higher than 29% of 412 peers (All). weak.

Rank 15 of 100: higher than 15% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+3.2% per year

Rank 40 of 100: higher than 40% of 437 peers (All). medium.

Rank 47 of 100: higher than 47% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−3.5% per year

Rank 13 of 100: higher than 13% of 399 peers (All). weak.

Rank 18 of 100: higher than 18% of 47 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+6.0% per year

Rank 35 of 100: higher than 35% of 375 peers (All). medium.

Rank 36 of 100: higher than 36% of 46 peers (Sector). medium.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 3.20 USD
  • met: Payout ratio at most 60% of earnings 37%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +7.4%
  • met: Free cash flow per share covers the dividend 3.8x
  • met: Dividends paid over the last 5 years covered by free cash flow 26% of free cash flow
Payout ratio

37% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+7.4% per year

Rank 50 of 100: higher than 50% of 321 peers (All). medium.

Rank 56 of 100: higher than 56% of 31 peers (Sector). medium.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

3.8x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 6 of 9
  • met: Long-term debt no higher than equity 0.79
  • met: Current assets cover current liabilities 1.04
  • met: Positive equity 7.2B USD
  • met: In 5 years, share count up by at most 5% −16.9%
  • met: Free cash flow positive in the last fiscal year 1.4B USD
Piotroski F-Score

6 of 9 Fiscal year 2025

Rank 45 of 100: higher than 45% of 310 peers (All). medium.

Rank 38 of 100: higher than 38% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.79 at fiscal year end

Rank 40 of 100: lower than 40% of 486 peers (All). medium.

Rank 29 of 100: lower than 29% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.04 at fiscal year end

Rank 31 of 100: higher than 31% of 513 peers (All). weak.

Rank 17 of 100: higher than 17% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−16.9% in 5 years

Rank 87 of 100: lower than 87% of 507 peers (All). strong.

Rank 89 of 100: lower than 89% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.2% per year), more slowly than the sector median.
  • Light red: Net income (total) shrank over 5 years (−7.1% per year); per share −3.5% per year.
  • Light yellow: Net margin 9.0%, below the sector median (13.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 7.5B USD · Net income 645.0M USD · Net margin 8.6%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 7.4B USD · Net income 772.0M USD · Net margin 10.4%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 7.5B USD · Net income 736.0M USD · Net margin 9.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 7.7B USD · Net income 858.0M USD · Net margin 11.1%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 9.4B USD · Net income 1.4B USD · Net margin 15.2%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 10.8B USD · Net income 2.0B USD · Net margin 18.5%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 9.9B USD · Net income 946.0M USD · Net margin 9.6%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 9.3B USD · Net income 854.0M USD · Net margin 9.2%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 9.9B USD · Net income 871.0M USD · Net margin 8.8%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 11.0B USD · Net income 992.0M USD · Net margin 9.0%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 11.0B USD · Net income 992.0M USD · Net margin 9.0%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +10.0% vs. the same quarter a year earlier; grown for 11 quarters in a row.

Revenue 12 months vs. prior 12
+9.1%
12 months: 11.8B USD · Fiscal year 2025: +11.8%
Net margin 12 months
9.5%
Fiscal year 2025: 9.0%
Free cash flow margin 12 months
11.6%
Fiscal year 2025: 12.3%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 11.0B USD + year to date to Sep 30, 2026 9.0B USD − same period a year earlier to Sep 30, 2025 8.2B USD = 11.8B USD
  • Net income: fiscal year to Dec 31, 2025 992.0M USD + year to date to Sep 30, 2026 884.0M USD − same period a year earlier to Sep 30, 2025 747.0M USD = 1.1B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 1.9B USD + year to date to Sep 30, 2026 1.5B USD − same period a year earlier to Sep 30, 2025 1.4B USD = 2.0B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 527.0M USD + year to date to Sep 30, 2026 418.0M USD − same period a year earlier to Sep 30, 2025 369.0M USD = 576.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 263.1B+10.0%312.0M10.1%
Apr–Jun 263.0B+10.2%320.0M10.5%
Jan–Mar 262.9B+9.2%252.0M8.7%
Oct–Dec 25*2.8B+7.1%245.0M8.7%
Jul–Sep 252.8B+13.2%245.0M8.7%
Apr–Jun 252.8B+15.2%282.0M10.2%
Jan–Mar 252.7B+12.1%220.0M8.3%
Oct–Dec 24*2.6B+14.6%222.0M8.5%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Oct 23, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.80x
backed from 1.0 · 3 years: 1.56x
Interest coverage
5.6x
well covered from 5 · 3 years: 6.3x
Tax rate
23.8%
for information only · 3 years: 23.0%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 1.9B USD ÷ group profit incl. minority interests 1.0B USD = 1.80x
  • Operating income 1.6B USD ÷ Interest expense 277.0M USD = 5.6x
  • Taxes 314.0M USD ÷ profit before tax 1.3B USD = 23.8%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.80x5.6x23.8%
20241.45x6.0x23.2%
20231.40x7.7x21.9%
20221.69x9.6x21.4%
20211.07x15.7x23.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and 3 years with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
3 of 10
revenue below the prior year
Net margin range
9.9 percentage points
from 8.6% to 18.5%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+11.8%9.0%
2024+6.7%8.8%
2023−6.4%9.2%
2022−8.4%9.6%
2021+14.3%18.5%
2020+22.1%15.2%
2019+2.6%11.1%
2018+1.7%9.8%
2017−1.5%10.4%
2016+0.3%8.6%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 33.2 USD gross profit, 14.1 USD operating income and 9.0 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue11.0B USD100.0%
Gross profit3.7B USD33.2%
Cost of revenue7.4B USD66.8%
Operating income1.6B USD14.1%
Operating expenses2.1B USD19.1%
Net income992.0M USD9.0%
Interest expense277.0M USD2.5%
Taxes & other (net)287.0M USD2.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 20.9% to 14.1%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 38.6% · Operating margin 17.0% · Net margin 8.6%
  2. Fiscal year 2017: Gross margin 40.4% · Operating margin 15.7% · Net margin 10.4%
  3. Fiscal year 2018: Gross margin 34.6% · Operating margin 14.6% · Net margin 9.8%
  4. Fiscal year 2019: Gross margin 34.8% · Operating margin 15.9% · Net margin 11.1%
  5. Fiscal year 2020: Gross margin 38.5% · Operating margin 20.9% · Net margin 15.2%
  6. Fiscal year 2021: Gross margin 39.0% · Operating margin 22.1% · Net margin 18.5%
  7. Fiscal year 2022: Gross margin 34.7% · Operating margin 14.4% · Net margin 9.6%
  8. Fiscal year 2023: Gross margin 33.0% · Operating margin 13.6% · Net margin 9.2%
  9. Fiscal year 2024: Gross margin 32.9% · Operating margin 13.6% · Net margin 8.8%
  10. Fiscal year 2025: Gross margin 33.2% · Operating margin 14.1% · Net margin 9.0%

Returns

Return on equity fell in 5 years from 21.2% to 13.8%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 13.9% · Return on assets 6.4%
  2. Fiscal year 2017: Return on equity 15.7% · Return on assets 7.4%
  3. Fiscal year 2018: Return on equity 14.1% · Return on assets 6.7%
  4. Fiscal year 2019: Return on equity 15.2% · Return on assets 6.7%
  5. Fiscal year 2020: Return on equity 21.2% · Return on assets 10.2%
  6. Fiscal year 2021: Return on equity 31.0% · Return on assets 14.7%
  7. Fiscal year 2022: Return on equity 16.1% · Return on assets 7.4%
  8. Fiscal year 2023: Return on equity 13.5% · Return on assets 6.1%
  9. Fiscal year 2024: Return on equity 12.9% · Return on assets 5.4%
  10. Fiscal year 2025: Return on equity 13.8% · Return on assets 6.1%

Equity and long-term debt

The equity ratio fell in 5 years from 48.2% to 44.2%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 4.6B USD · Long-term debt 3.7B USD
  2. Fiscal year 2017: Equity 4.9B USD · Long-term debt 3.8B USD
  3. Fiscal year 2018: Equity 5.2B USD · Long-term debt 3.9B USD
  4. Fiscal year 2019: Equity 5.6B USD · Long-term debt 4.8B USD
  5. Fiscal year 2020: Equity 6.8B USD · Long-term debt 4.0B USD
  6. Fiscal year 2021: Equity 6.4B USD · Long-term debt 4.0B USD
  7. Fiscal year 2022: Equity 5.9B USD · Long-term debt 4.0B USD
  8. Fiscal year 2023: Equity 6.3B USD · Long-term debt 4.7B USD
  9. Fiscal year 2024: Equity 6.8B USD · Long-term debt 6.2B USD
  10. Fiscal year 2025: Equity 7.2B USD · Long-term debt 5.7B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.72 to 1.04.

Current ratio
  1. Fiscal year 2016: Current ratio 1.56
  2. Fiscal year 2017: Current ratio 1.24
  3. Fiscal year 2018: Current ratio 0.94
  4. Fiscal year 2019: Current ratio 1.25
  5. Fiscal year 2020: Current ratio 1.72
  6. Fiscal year 2021: Current ratio 1.56
  7. Fiscal year 2022: Current ratio 1.22
  8. Fiscal year 2023: Current ratio 1.31
  9. Fiscal year 2024: Current ratio 1.10
  10. Fiscal year 2025: Current ratio 1.04

Cash flow

Free cash flow fell in 5 years from 1.6B USD to 1.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 1.1B USD · Capital expenditure 293.0M USD · Free cash flow 776.0M USD
  2. Fiscal year 2017: Operating cash flow 1.2B USD · Capital expenditure 252.0M USD · Free cash flow 923.0M USD
  3. Fiscal year 2018: Operating cash flow 1.2B USD · Capital expenditure 383.0M USD · Free cash flow 817.0M USD
  4. Fiscal year 2019: Operating cash flow 1.2B USD · Capital expenditure 400.0M USD · Free cash flow 843.0M USD
  5. Fiscal year 2020: Operating cash flow 2.0B USD · Capital expenditure 418.0M USD · Free cash flow 1.6B USD
  6. Fiscal year 2021: Operating cash flow 2.2B USD · Capital expenditure 403.0M USD · Free cash flow 1.8B USD
  7. Fiscal year 2022: Operating cash flow 1.7B USD · Capital expenditure 404.0M USD · Free cash flow 1.3B USD
  8. Fiscal year 2023: Operating cash flow 1.3B USD · Capital expenditure 408.0M USD · Free cash flow 864.0M USD
  9. Fiscal year 2024: Operating cash flow 1.3B USD · Capital expenditure 425.0M USD · Free cash flow 909.0M USD
  10. Fiscal year 2025: Operating cash flow 1.9B USD · Capital expenditure 527.0M USD · Free cash flow 1.4B USD

Share count

The share count fell in 5 years by 16.9% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 142.0M
  2. Fiscal year 2017: Diluted share count 140.0M
  3. Fiscal year 2018: Diluted share count 139.0M
  4. Fiscal year 2019: Diluted share count 136.0M
  5. Fiscal year 2020: Diluted share count 136.0M
  6. Fiscal year 2021: Diluted share count 128.0M
  7. Fiscal year 2022: Diluted share count 118.0M
  8. Fiscal year 2023: Diluted share count 113.0M
  9. Fiscal year 2024: Diluted share count 113.0M
  10. Fiscal year 2025: Diluted share count 113.0M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Net margin

The net margin fell in 5 years from 15.2% to 9.0%.

DGX Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: DGX 8.6%
  2. Fiscal year 2017: DGX 10.4%
  3. Fiscal year 2018: DGX 9.8%
  4. Fiscal year 2019: DGX 11.1%
  5. Fiscal year 2020: DGX 15.2%
  6. Fiscal year 2021: DGX 18.5%
  7. Fiscal year 2022: DGX 9.6%
  8. Fiscal year 2023: DGX 9.2%
  9. Fiscal year 2024: DGX 8.8%
  10. Fiscal year 2025: DGX 9.0% · Sector today 13.2%

Return on equity

Return on equity fell in 5 years from 21.2% to 13.8%.

DGX Sector today 14.1%
  1. Fiscal year 2016: DGX 13.9%
  2. Fiscal year 2017: DGX 15.7%
  3. Fiscal year 2018: DGX 14.1%
  4. Fiscal year 2019: DGX 15.2%
  5. Fiscal year 2020: DGX 21.2%
  6. Fiscal year 2021: DGX 31.0%
  7. Fiscal year 2022: DGX 16.1%
  8. Fiscal year 2023: DGX 13.5%
  9. Fiscal year 2024: DGX 12.9%
  10. Fiscal year 2025: DGX 13.8% · Sector today 14.1%

Free cash flow margin

The free cash flow margin fell in 5 years from 16.8% to 12.3%.

DGX Sector today 14.7%
  1. Fiscal year 2016: DGX 10.3%
  2. Fiscal year 2017: DGX 12.5%
  3. Fiscal year 2018: DGX 10.8%
  4. Fiscal year 2019: DGX 10.9%
  5. Fiscal year 2020: DGX 16.8%
  6. Fiscal year 2021: DGX 17.0%
  7. Fiscal year 2022: DGX 13.3%
  8. Fiscal year 2023: DGX 9.3%
  9. Fiscal year 2024: DGX 9.2%
  10. Fiscal year 2025: DGX 12.3% · Sector today 14.7%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 3.8x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+7.4%
dividend per share, average per year
Coverage by free cash flow
3.8x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 2.24 USD → fiscal year 2025 3.20 USD = +7.4% per year
  • Free cash flow per share 12.03 USD ÷ dividend per share 3.20 USD = 3.8x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.20 USD · Fiscal year 2025
Dividend growth per year
3 y +6.6%5 y +7.4%10 y +7.7%
Payout ratio
of earnings 37% of free cash flow 26%
To shareholders (5 years)
6.1B USD 74% through repurchases
Share count over 5 years
−16.9% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 2.24 USD to 3.20 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.65 USD
  2. Fiscal year 2017: Dividend per share 1.80 USD
  3. Fiscal year 2018: Dividend per share 2.03 USD
  4. Fiscal year 2019: Dividend per share 2.12 USD
  5. Fiscal year 2020: Dividend per share 2.24 USD
  6. Fiscal year 2021: Dividend per share 2.48 USD
  7. Fiscal year 2022: Dividend per share 2.64 USD
  8. Fiscal year 2023: Dividend per share 2.84 USD
  9. Fiscal year 2024: Dividend per share 3.00 USD
  10. Fiscal year 2025: Dividend per share 3.20 USD

Payout ratios

The payout ratio rose in 5 years from 21.4% to 36.6%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 36.6% · Payout ratio (free cash flow) 28.7%
  2. Fiscal year 2017: Payout ratio (earnings) 32.7% · Payout ratio (free cash flow) 26.8%
  3. Fiscal year 2018: Payout ratio (earnings) 38.4% · Payout ratio (free cash flow) 32.6%
  4. Fiscal year 2019: Payout ratio (earnings) 33.8% · Payout ratio (free cash flow) 33.9%
  5. Fiscal year 2020: Payout ratio (earnings) 21.4% · Payout ratio (free cash flow) 18.7%
  6. Fiscal year 2021: Payout ratio (earnings) 15.9% · Payout ratio (free cash flow) 16.9%
  7. Fiscal year 2022: Payout ratio (earnings) 33.1% · Payout ratio (free cash flow) 23.2%
  8. Fiscal year 2023: Payout ratio (earnings) 37.9% · Payout ratio (free cash flow) 36.3%
  9. Fiscal year 2024: Payout ratio (earnings) 39.0% · Payout ratio (free cash flow) 36.4%
  10. Fiscal year 2025: Payout ratio (earnings) 36.6% · Payout ratio (free cash flow) 26.0%

What goes back to shareholders

Over 5 years, 6.1B USD went back to shareholders, 74% of it through share repurchases. That is 97% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 223.0M USD · Share repurchases 590.0M USD · New shares issued (including employee plans) not available · Free cash flow 776.0M USD
  2. Fiscal year 2017: Dividends paid 247.0M USD · Share repurchases 465.0M USD · New shares issued (including employee plans) not available · Free cash flow 923.0M USD
  3. Fiscal year 2018: Dividends paid 266.0M USD · Share repurchases 322.0M USD · New shares issued (including employee plans) not available · Free cash flow 817.0M USD
  4. Fiscal year 2019: Dividends paid 286.0M USD · Share repurchases 353.0M USD · New shares issued (including employee plans) not available · Free cash flow 843.0M USD
  5. Fiscal year 2020: Dividends paid 297.0M USD · Share repurchases 325.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  6. Fiscal year 2021: Dividends paid 309.0M USD · Share repurchases 2.2B USD · New shares issued (including employee plans) not available · Free cash flow 1.8B USD
  7. Fiscal year 2022: Dividends paid 305.0M USD · Share repurchases 1.4B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  8. Fiscal year 2023: Dividends paid 314.0M USD · Share repurchases 275.0M USD · New shares issued (including employee plans) not available · Free cash flow 864.0M USD
  9. Fiscal year 2024: Dividends paid 331.0M USD · Share repurchases 151.0M USD · New shares issued (including employee plans) not available · Free cash flow 909.0M USD
  10. Fiscal year 2025: Dividends paid 353.0M USD · Share repurchases 450.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.4B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Quest Diagnostics next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison DGX, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
DGX Quest Diagnostics this stock 11.0B USD +3.2%33.2%14.1%9.0%13.8%44.2%12.3%6/9
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
Median of the sector 27 symbols 44.3B USD +8.4%67.2%17.8%13.2%14.1%38.5%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector DGX next to VRTX – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.2% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 3.2% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−7.1% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: −3.5% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 7.1% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

9.0% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 8.99 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 15.2%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.73 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.73 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
11.0B USD
Revenue vs. prior year
+11.8%
Net income (FY)
992.0M USD
Net income vs. prior year
+13.9%
EPS (FY)
8.75 USD
Superinvestors holding
1 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Sep 30, 2026 (filed Oct 23, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 11.0B992.0M 9.0% 8.75 – –
2024Dec 31, 2024 9.9B871.0M 8.8% 7.69 – –
2023Dec 31, 2023 9.3B854.0M 9.2% 7.49 – –
2022Dec 31, 2022 9.9B946.0M 9.6% 7.97 – –
2021Dec 31, 2021 10.8B2.0B 18.5% 15.55 – –
2020Dec 31, 2020 9.4B1.4B 15.2% 10.47 – –
2019Dec 31, 2019 7.7B858.0M 11.1% 6.28 – –
2018Dec 31, 2018 7.5B736.0M 9.8% 5.29 – –
2017Dec 31, 2017 7.4B772.0M 10.4% 5.50 1.80 33%
2016Dec 31, 2016 7.5B645.0M 8.6% 4.51 1.65 37%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 3.1B312.0M 10.1% 2.78 0.86 31%
Q2/26Jun 30, 2026 3.0B320.0M 10.5% 2.84 0.86 30%
Q1/26Mar 31, 2026 2.9B252.0M 8.7% 2.24 0.86 38%
Q4/25*Dec 31, 2025 2.8B245.0M 8.7% – 0.80 –
Q3/25Sep 30, 2025 2.8B245.0M 8.7% 2.16 0.80 37%
Q2/25Jun 30, 2025 2.8B282.0M 10.2% 2.47 0.80 32%
Q1/25Mar 31, 2025 2.7B220.0M 8.3% 1.94 0.80 41%
Q4/24*Dec 31, 2024 2.6B222.0M 8.5% – 0.75 –
Q3/24Sep 30, 2024 2.5B226.0M 9.1% 1.99 0.75 38%
Q2/24Jun 30, 2024 2.4B229.0M 9.6% 2.03 0.75 37%
Q1/24Mar 31, 2024 2.4B194.0M 8.2% 1.72 0.75 44%
Q4/23*Dec 31, 2023 2.3B192.0M 8.4% – 0.71 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $19.8M6 people −$19.8M
6 months $00 people $23.7M8 people −$23.7M
12 months $00 people $47.4M9 people −$47.4M

Latest transactions

  • Nov 13, 2026 Deppe Michael J Officer Open-market sale · 10b5-1 plan 5,515 shares · $1.4M · SEC
  • Nov 13, 2026 Deppe Michael J Officer Open-market sale · 10b5-1 plan 6,261 shares · $1.6M · SEC
  • Nov 9, 2026 Plewman Patrick Officer Open-market sale · 10b5-1 plan 650 shares · $167.3K · SEC
  • Nov 9, 2026 Plewman Patrick Officer Open-market sale · 10b5-1 plan 6,793 shares · $1.7M · SEC
  • Nov 9, 2026 Plewman Patrick Officer Open-market sale · 10b5-1 plan 4,274 shares · $1.1M · SEC
  • Nov 3, 2026 Doherty Catherine T. Officer Open-market sale · 10b5-1 plan 2,907 shares · $730.4K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Quest Diagnostics?

All superinvestor portfolios

1 of 26 tracked superinvestors reports a position.

Superinvestors with a position in Quest Diagnostics, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates < 0.1% −5.5% reduced Q3 2026

Sold out in the latest quarter: Steve Cohen.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on DGX yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: DGX

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close